What's new in gynecology and obstetrics

Journal of the American College of Surgeons

Volumn 201, Issue 2, 2005, Pages 265-274

  Bodurka, Diane C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CLOMIFENE; CLOMIFENE CITRATE; ESTROGEN; GESTAGEN; METFORMIN; PLACEBO; VIRUS VACCINE;

ABDOMINAL HYSTERECTOMY; ABORTION; CANCER; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIUM CANCER; FAMILIAL CANCER; FERTILITY; GYNECOLOGY; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; LAPAROSCOPIC SURGERY; MINIMALLY INVASIVE SURGERY; MORTALITY; OBSTETRICS; OVARY POLYCYSTIC DISEASE; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURGICAL TECHNIQUE; UTERINE ARTERY EMBOLIZATION; UTERINE CERVIX CANCER; UTERINE TUBE LIGATION; VACCINIA VIRUS; VAGINAL HYSTERECTOMY; VIRUS INFECTION;

EID: 22244444466     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2005.05.020     Document Type: Article

References (68)

1. Walker J, Schlaerth J, Spiegel G, Kornblith A. A Phase III randomized clinical trial of laparoscopic pelvic and para aortic node sampling with vaginal hysterectomy and BSO versus open laparotomy with pelvin and para aortic node sampling and abdominal hysterectomy and BSO in endometrial adenocarcinoma and uterine sarcoma, clinical stage I, IIA, Grade I, II, III, in GOG Protocol #LAP-2 2005, UTMD. Anderson Cancer Center: Houston, TX.
2. D.S. Chi, N.R. Abu-Rustum, Y. Sonoda The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers Am J Obstet Gynecol 192 2005 1614 1619
3. E. Leblanc, D. Querleu, F. Narducci Laparoscopic restaging of early stage invasive adnexal tumors 10-year experience Gynecol Oncol 94 2004 624 629
4. M. Plante, M.C. Renaud, H. Francois, M. Roy Vaginal radical trachelectomyan: oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature Gynecol Oncol 94 2004 614 623
5. P. Morice Regarding "First case of a centropelvic recurrence after radical trachelectomy literature review and implications for the preoperative selection of patients Gynecol Oncol 92 2004 1002 1005
6. P. Morice, R. Tozzi, C. Kohler First case of a centropelvic recurrence after radical trachelectomy literature review and implications for the preoperative selection of patients Gynecol Oncol 92 2004 1002 1005
7. P. Klemm, R. Tozzi, C. Kohler, H. Hertel Does radical trachelectomy influence uterine blood supply? Gynecol Oncol 96 2005 283 286
8. H. Steed, B. Rosen, J. Murphy A comparison of laparascopic-assisted radical vaginal hysterectomy and radical abdominal hysterectomy in the treatment of cervical cancer Gynecol Oncol 93 2004 588 593
9. J.B. Spies, J.M. Cooper, R. Worthington-Kirsch Outcome of uterine embolization and hysterectomy for leiomyomas results of a multicenter study Am J Obstet Gynecol 191 2004 22 31
10. W.J. Smith, E. Upton, E.J. Shuster Patient satisfaction and disease specific quality of life after uterine artery embolization Am J Obstet Gynecol 190 2004 1697 1703 discussion 1703-1706
11. J. Goldberg, T. Hyslop, J.E. Tolosa, C. Sultana Racial differences in severe perineal lacerations after vaginal delivery Am J Obstet Gynecol 188 2003 1063 1067
12. J.F. Greene, P.F. Schnatz, M.J. Hallisey Fertility outcomes after uterine artery embolization Obstet Gynecol 105 2005 67S 68S
13. J.J. Walker Pre-eclampsia Lancet 356 2000 1260 1265
14. J.M. Roberts, D.W. Cooper Pathogenesis and genetics of pre-eclampsia Lancet 357 2001 53 56
15. R.J. Levine, S.E. Maynard, C. Qian Circulating angiogenic factors and the risk of preeclampsia N Engl J Med 350 2004 672 683
16. R.J. Levine, R. Thadhani, C. Qian Urinary placental growth factor and risk of preeclampsia JAMA 293 2005 77 85
17. C.S. Buhimschi, E.R. Norwitz, E. Funai Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia Am J Obstet Gynecol 192 2005 734 741
18. J.P. Struewing, P. Hartge, S. Wacholder The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 1997 1401 1408
19. A.C. Antoniou, S.A. Gayther, J.F. Stratton Risk models for familial ovarian and breast cancer Genet Epidemiol 18 2000 173 190
20. D.F. Easton, D. Ford, D.T. Bishop Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Am J Hum Genet 56 1995 265 271
21. P.A. Meeuwissen, C. Seynaeve, C.T. Brekelmans Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer Gynecol Oncol 97 2005 476 482
22. R.I. Olivier, M. van Beurden, M.A. Lubsen Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up Br J Cancer 90 2004 1492 1497
23. M.J. Casey, C. Synder, C. Bewtra Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations Gynecol Oncol 97 2005 457 467
24. K.A. Metcalfe, H.T. Lynch, P. Ghadirian The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers Obstet Gynecol Surv 60 2005 235 236
25. M.G. Dunlop, S.M. Farrington, A.D. Carothers Cancer risk associated with germline DNA mismatch repair gene mutations Hum Mol Genet 6 1997 105 110
26. M. Aarnio, R. Sankila, E. Pukkala Cancer risk in mutation carriers of DNA-mismatch-repair genes Int J Cancer 81 1999 214 218
27. P. Watson, K.M. Lin, M.A. Rodriguez-Bigas Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members Cancer 83 1998 259 266
28. K. Lu, M. Dinh, W. Kohlmann Gynecological malignancy as a "Sentinel Cancer" for women with HNPCC Gynecol Oncol 92 2004 421
29. L. Koutsky Epidemiology of genital human papilloma virus infection Am J Med 102 1997 3 8
30. J.L. Gerberding Report to Congress Prevention of genital human papilloma virus infection 2004 Centers for Disease Control and Prevention, Department of Health and Human Services Washington, DC
31. W. Cates American Social Health Association Panel Estimates of the incidence and prevalence of sexually transmitted diseases in the United States Sex Transm Dis 26 1999 S2 S7
32. S.K. Kjaer, A.J. van den Brule, G. Paull Type specific persistence of high risk human papilloma virus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women population based prospective follow-up study Br Med J 325 2002 1 7
33. J. Cuzik, P. Sasieni, P. Davies A systematic review of the role of human papillomavirus testing within a cervical screening program Health Technology Assessment 3 1999 1 11
34. E.M. Burd Human papilloma virus and cervical cancer Clin Microbiol Rev 16 2003 1 17
35. A.B. Moscicki, N. Hills, S. Shiboski Risks for incident human papilloma virus infection and low-grade squamous intraepithelial lesion development in young females JAMA 285 2001 2995 3002
36. F.X. Bosch, M.M. Manos, N. Munoz International Biological Study on Cervical Cancer (IBSCC) Study Group Prevalence of human papilloma virus in cervical cancer a worldwide perspective J Natl Cancer Inst 87 1995 796 802
37. K. D'Hauwers, W.A. Tjalma, C.E. Depuydt Human papilloma virus infections in women the potential role of male transmission Int J Gynecol Cancer 4 2004 28 38
38. M. Schiffman, S.K. Kjaer Chapter 2 natural history of anogenital human papillomavirus infection and neoplasia J Natl Cancer Inst Monogr 31 2003 14 19
39. C. Depuydt, A.J. Vereecken, G.M. Salembier Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papilloma virus DNA in Flemish women Br J Cancer 88 2003 560 566
40. S. Dermime, D.E. Gilham, D.M. Shaw Vaccine and antibody-directed T cell tumour immunotherapy Biochim Biophys Acta 1704 2004 11 35
41. W.A.A. Tjalma, M. Arbyn, J. Paavonen Prophylactic human papilloma virus vaccines the beginning of the end of cervical cancer Int J Gynecol Cancer 14 2004 751 761
42. T.T. Tomson, R.B.S. Roden, T.-C. Wu Human papilloma virus vaccines for the prevention and treatment of cervical cancer Curr Opin Investigational Drugs 5 2004 1247 1261.
43. C.L. Rock, C.W. Michael, R.K. Reynolds Prevention of cervix cancer Crit Rev Oncol Hematol 33 2000 169 185
44. D. Nardelli-Haefliger, D. Wirthner, J.T. Schiller Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papilloma virus 16 virus-like particles J Natl Cancer Inst 95 2003 1128 1137
45. C.D. Harro, C.D. Harro, Y.Y. Pang Safety and immunogenicity trial in adult volunteers of a human papilloma virus 16 L1 virus-like particle vaccine J Natl Cancer Inst 93 2001 284 292
46. T.G. Evans, W. Bonnez, R.C. Rose A phase 1 study of a recombinant virus like particle vaccine against human papilloma virus type 11 in healthy adult volunteers J Infect Dis 183 2001 1485 1493
47. L.A. Koutsky, K.A. Ault, C.M. Wheeler A controlled trial of a human papilloma virus type 16 vaccine N Engl J Med 347 2002 1645 1651
48. K.U. Jansen, A.R. Shaw Human papilloma virus vaccines and prevention of cervical cancer Annu Rev Med 55 2004 319 331
49. A. Billich HPV vaccine MedImmune/GlaxoSmithKline Curr Opin Investig Drugs 4 2003 210 213
50. A.M. Kaufmann, P.L. Stern, E.M. Rankin Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papilloma virus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer Clin Cancer Res 8 2002 3676 3685
51. M. Adams, L. Borysiewicz, A. Fiander Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer Vaccine 19 2001 2549 2556
52. L.K. Borysiewicz, A. Fiander, M. Nimako A recombinant vaccinia virus encoding human papilloma virus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer Lancet 347 1996 1523 1527
53. P.J. Baldwin, S.H. van der Burg, C.M. Boswell Vaccinia-expressed human papilloma virus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia Clin Cancer Res 9 2003 5205 5213
54. M.E. Ressing, W.J. van Driel, R.M. Brandt Detection of T helper responses, but not of human papilloma virus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma J Immunother 23 2000 255 266
55. W.J. van Driel, M. Ressing, G. Kenter Vaccination with HPV16 peptides of patients with advanced cervical carcinoma clinical evaluation of a phase I-II trial Eur J Cancer 35 1999 946 952
56. L. Muderspach, S. Wilczynski, L. Roman A phase I trial of a human papilloma virus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive Clin Cancer Res 6 2000 3406 3416
57. S. Hallez, P. Simon, F. Maudoux Phase I/II trial of immunogenicity of a human papilloma virus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia Cancer Immunol Immunother 53 2004 642 650
58. N.R. Chu Therapeutic vaccination for the treatment of mucosotropic human papilloma virus-associated disease Expert Opin Biol Ther 3 2003 477 486
59. J.M. Berry, J.M. Palefsky A review of human papilloma virus vaccines from basic science to clinical trials From Biosci 8 2003 s333 s345
60. Slomovitz BM, Sun C, Frumovitz M, et al. Are women ready for the cervical cancer vaccine? Gynecol Oncol. In Press.
61. N. Munoz, F.X. Bosch, X. Castellsague Against which human papilloma virus types shall we vaccinate and screen? The international perspective Int J Cancer 111 2004 278 285
62. I. Stein, M. Leventhal Amenorrhea associated with bilateral polycystic ovaries Am J Obstet Gynecol 1935 1935 181 191
63. J.S. Archer, R.J. Chang Hirsutism and acne in polycystic ovary syndrome Best Pract Res Clin Obstet Gynaecol 18 2004 737 754
64. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod 19 2004 41 47
65. F. Orio Jr, S. Palomba, L. Spinelli The cardiovascular risk of young women with polycystic ovary syndrome an observational, analytical, prospective case-control study J Clin Endocrinol Metab 89 2004 3696 3701
66. R.L. Barbieri, A.R. Gargiulo Metformin for the treatment of the polycystic ovary syndrome Minerva Ginecol 56 2004 63 79
67. J. Aruna, S. Mittal, S. Kumar Metformin therapy in women with polycystic ovary syndrome Int J Gynaecol Obstet 87 2004 237 241
68. S. Kashyap, G.A. Wells, Z. Rosenwaks Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome Hum Reprod 19 2004 2474 2483